Notable things mentioned or implied that I can remember:
-They've spent 30M on IP and production capabilities. A major issue for shareholders is the level of debt/cash burn vs. revenue, now if they have spent it properly, then AEB is incredibly undervalued. Very good to hear that number in the open by the CEO. It shows confidence they have something to show for. (If you connect the dots, then you may start to understand why MCL/QBL is interested in a partnership with AEB - watch closely some of the machinery they show)
-Not much on medicinal cannabis, the production side of it being delayed clearly means the focus is now on getting the algae neutraceutical part of the ground, however they have mentioned a CBD+ Algae product - Let me tell you one thing, this will be a best seller, and will have health synergistic effects !
-Plant in India, seems it's moving fairly quickly.
Anyway, judge for yourself.
AEB Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held